KENZAR Losartan Potassium 50mg Film-Coated Tablet 1's
RXDRUG-DRP-2215-1pc
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
Kenzar
Full Details
Dosage Strength
50 mg
Drug Ingredients
- Losartan Potassium
Drug Packaging
Film-Coated Tablet 1's
Generic Name
Losartan Potassium
Dosage Form
Film-Coated Tablet
Registration Number
DRP-2215
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
It is used in the management of hypertension, particularly in the patients who develop cough with Angiotensin Converting Enzyme (ACE) Inhibitors and to reduce the risk of stroke in patients with left ventricular hypertrophy and in the treatment of diabetic nephropathy.
Dosage/Direction for Use
In hypertension, the usual starting and maintenance dose is 50 mg once daily. The dose may be increased if necessary to 100 mg daily based on blood pressure response in one or two divided doses.
For patients with intravascular volume-depletion (e.g., those treated with high-dose diuretics) a starting dose of 25 daily should be considered.
An initial dose of 25 mg once daily is suggested for the elderly over 75 years of age.
Losartan potassium (KENZAR) may be administered with or without food.
In diabetic nephropathy, an initial dose of 50 mg once daily. increased to 100 mg once daily depending on blood pressure.
For patients with intravascular volume-depletion (e.g., those treated with high-dose diuretics) a starting dose of 25 daily should be considered.
An initial dose of 25 mg once daily is suggested for the elderly over 75 years of age.
Losartan potassium (KENZAR) may be administered with or without food.
In diabetic nephropathy, an initial dose of 50 mg once daily. increased to 100 mg once daily depending on blood pressure.
Administration
May be taken with or without food.
Contraindications
Losartan potassium is contraindicated in patients who are hypersensitive to any component of this product.
Use In Pregnancy & Lactation
Should not be given during pregnancy and lactation.
Adverse Reactions
Adverse effects have been reported to be usually mild and transient in nature. The most common drug-related side effects were dizziness, asthenia/fatigue and vertigo. The overall incidence of side effects reported with Losartan potassium was comparable to placebo.
Drug Interactions
In clinical pharmacokinetic trials, no drug interactions of clinical significance have been identified with hydrochlorothiazide, digoxin, warfarin, cimetidine, phenobarbital, ketoconazole, and erythromycin. Rifampin and fluconazole have been reported to reduce levels of active metabolite. The clinical consequences of these interactions have not been evaluated.
As with other drugs that block angiotensin II or its effects.
Concomitant use of potassium-sparing diuretics (e.g. spironolactone, triamterene, amiloride) potassium supplements or salt-containing potassium may lead to increases in serum potassium.
As with other antihypertensive agents, the antihypertensive effect of losartan may be attenuated by the non-steroidal anti-inflammatory drug indomethacin.
As with other drugs that block angiotensin II or its effects.
Concomitant use of potassium-sparing diuretics (e.g. spironolactone, triamterene, amiloride) potassium supplements or salt-containing potassium may lead to increases in serum potassium.
As with other antihypertensive agents, the antihypertensive effect of losartan may be attenuated by the non-steroidal anti-inflammatory drug indomethacin.
Storage
Store at temperatures not exceeding 30°C. Protect from light.
Action
Pharmacology: Pharmacokinetics: Losartan potassium (KENZAR) is readily absorbed from the gastrointestinal tract following oral administration. It undergoes first pass metabolism to form an active carboxylic acid metabolite which has a greater pharmacological activities. Peak plasma concentration is achieved in about 1 hour after an oral dose. It is 98% bound to plasma protein. It is excreted in urine and in feces as unchanged drug and metabolites. Following oral dose, about 4% of the dose is excreted unchanged in urine and about 6% in urine as the active metabolite.
MedsGo Class
Angiotensin II Antagonists
Please sign in so that we can notify you about a reply